Invega Sustenna Prescribing & Dosing Schedule

Q: What is the dosage of Invega?

Invega is available in 5 dosages, including 156 mg/ml Prefilled Syringe 0.25 ml, 156 mg/ml Prefilled Syringe 0.5 ml, 156 mg/ml Prefilled Syringe 0.75 ml, 156 mg/ml Prefilled Syringe 1 ml and 156 mg/ml Prefilled Syringe 1.5 ml

Q: What does Invega treat?

Invega treats Bipolar Disorder, Depressive Disorder and Schizophrenia

Q: What is Invega made of?

Invega contains paliperidone which is a Atypical Antipsychotic

Q: How is Invega administered?

Invega is administered as a Injectable

Dosage & Administration Drug label Prior authorization Financial assistance Patient education People also ask

Invega Sustenna (paliperidone palmitate)

Invega Sustenna 39 MG in 0.25 mL Prefilled Syringe

BOXED WARNING

Dosage & Administration

* For intramuscular injection only. ( 2.1)
* Each injection must be administered only by a healthcare professional. ( 2.1)
* For deltoid injection, use 1-inch 23G needle for patients weighing less than 90 kg or 1½-inch 22G needle for patients weighing 90 kg or more. For gluteal injection, use 1½-inch 22G needle regardless of patient weight. ( 2.1)

Indication	Initiation Dosing (deltoid)		Monthly Maintenance Dose * (deltoid or gluteal)	Maximum Monthly Dose
Indication	Day 1	Day 8	Monthly Maintenance Dose * (deltoid or gluteal)	Maximum Monthly Dose
* Administered 5 weeks after the first injection. * The recommended maintenance dose for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg). * Adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.
Schizophrenia ( 2.2)	234 mg	156 mg	39–234 mg †	234 mg
Schizoaffective disorder ( 2.2)	234 mg	156 mg	78–234 mg ‡	234 mg

* For patients naïve to oral paliperidone or oral or injectable risperidone, establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA SUSTENNA ®. ( 2.2)
* Missed Doses: To manage either a missed second initiation dose or a missed monthly maintenance dose, refer to the Full Prescribing Information. ( 2.3)
* Moderate to severe renal impairment (creatinine clearance < 50 mL/min):INVEGA SUSTENNA ®is not recommended. ( 2.5)
* Mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min):Administer 156 mg on treatment Day 1 and 117 mg on Day 8, both in the deltoid muscle. Follow with the recommended monthly maintenance dose of 78 mg, administered in the deltoid or gluteal muscle. Adjust monthly maintenance dose based on tolerability and/or efficacy within the strengths of 39 mg, 78 mg, 117 mg, or 156 mg. The maximum monthly dose is 156 mg for patients with mild renal impairment. ( 2.5)

drug label

Invega Sustenna Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

prior authorization

Invega Sustenna Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jun 26, 2024Arizona - Uniform Prior Authorization Form

Verified: Jun 26, 2024Colorado - Uniform Prior Authorization Form

Verified: Jun 26, 2024Hawaii - Uniform Prior Authorization Form

Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form

Verified: Jun 26, 2024Indiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Louisiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Minnesota - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Mexico - Uniform Prior Authorization Form

Verified: Jun 26, 2024Oregon - Uniform Prior Authorization Form

Verified: Jun 26, 2024Texas - Uniform Prior Authorization Form

Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form

Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form

Coverage Authorization Request

financial assistance

Invega Sustenna Financial Assistance Options

Copay savings program

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

patient education

Invega Sustenna Patient Education

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link